GlassScriptPhysician profile
Santokh Walha
NPI 1164409561
$5,293.80
in general payments reported to CMS, 2019-2025
18 companies · $995 in 2025
The $995 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $389 · 2021: $651 · 2022: $736 · 2023: $925 · 2024: $850 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,770.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,469.19 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,062.16 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,004.61 | 2021-2025 | Vraylar |
| Boston Scientific Corporation | $253.33 | 2024-2025 | General - Therapies |
| Lilly USA, LLC | $244.56 | 2020-2024 | Mounjaro |
| Pfizer INC. | $233.18 | 2020-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.68 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $194.28 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.93 | 2019-2022 | |
| Amgen INC. | $108.77 | 2019 | |
| Portola Pharmaceuticals, LLC | $94.64 | 2020 | |
| Spinefrontier, INC. | $72.64 | 2025 | Inspan, Facetfuse, Nanofuse |
| Novo Nordisk INC | $60.55 | 2020-2024 | Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $49.78 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $33.94 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.16 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.69 | 2021 | |
| Almatica Pharma LLC | $13.71 | 2023 | Sertraline Hcl, Loreev Xr, Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Santokh Walha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.